AnaConDa-therapy in COVID-19 Patients

About This Study

COVID 19-pneumonia may evolve into respiratory insufficiency for which invasive mechanical ventilation is required. Recently, inhaled anesthetics have become available for sedation of critically ill patients. Based upon recent research, these anesthetics may provide advantages in improvement of P/F ratio in ARDS patients. However, up to now, its effects on COVID-19 pneumonia patients is unknown; therefore, this study was designed as a plan to investigate whether the use of inhaled sevoflurane leads to improvement of oxygenation compared to intravenous sedatives in mechanically ventilated COVID-19 patients

Conditions Studied

Interventions

• •Sevoflurane

Eligibility

Inclusion Criteria:

* Age \>18 years
* More than 24 hours of invasive mechanical ventilation needed
* Positive test (e.g. Polymerase Chain Reaction (PCR)) for SARS-CoV-2

Exclusion Criteria:

* pulmonary history
* known allergy or hypersensitivity for halogenated anesthetics
* known or suspected predisposition for malignant hyperthermia
* suspected or proven intracranial hypertension
* severe liver dysfunction and/or icterus (serum bilirubin \>42,8-51,3 μg per liter)
* neutropenia (\<0.5X10\^9 neutrophils per liter)
* chemotherapy in the month prior to ICU admission
* patients that are transported to other hospitals during admission

Study Locations (1)